It is recommended to monitor blood pressure at baseline and during follow-up visits. Monitor quality of life based on the overactive bladder questionnaire (OAB-q) to assess the response to therapy.

The liver’s CYP450 system predominantly metabolizes mirabegron. Monitoring and dose adjustment should occur with patients on other medications with a narrow therapeutic index and also undergo metabolism via CYP2D6.